Human conventional siRNA, standard, TP53

The human conventional siRNA targeting TP53 is a key tool for gene silencing research, designed to specifically target the TP53 gene—a critical tumor suppressor gene with extensive implications in cellular biology and oncology. Also known as tumor protein p53, the TP53 gene has multiple aliases including BCC7, LFS1, and TRP53, reflecting its diverse biological roles and research significance.
Wild-type TP53 (wtp53) regulates essential cellular processes such as cell cycle arrest, apoptosis, DNA damage repair, and inhibition of angiogenesis and metastasis. However, mutations in TP53 are prevalent in various malignant tumors, leading to the loss of its tumor suppressor function and the acquisition of gain-of-function (GOF) properties by mutant p53 (mp53). These GOF traits contribute to tumor cell proliferation, chemotherapy resistance, and disease progression, making mp53 a prime target for cancer research and therapeutic development.
Small interfering RNA (siRNA) operates by specifically degrading complementary target mRNA, enabling precise inhibition of target protein expression. The human conventional TP53 siRNA leverages this RNA interference (RNAi) mechanism to silence TP53 expression, providing researchers with a powerful tool to dissect the functional roles of both wild-type and mutant TP53 in physiological and pathological processes.

Store at -20°C~-80°C.

Synthetic origin ensures high purity and consistent performance, with a purification level exceeding 97%.
Species-specific design optimized for human cells, ensuring targeted reactivity and minimizing off-target effects.
Conventional chemical synthesis format, purified by HPLC to remove unpaired single strands and impurities.
20–25 nucleotide double-stranded RNA structure, conforming to the standard siRNA length for efficient RNAi activation.
Compatible with standard in vitro cell culture systems and common transfection methods, facilitating seamless integration into existing research workflows.

Investigation of TP53 gene function, including the biological effects of wild-type and mutant p53 in cellular processes.
Research on tumorigenesis mechanisms, particularly the role of TP53 mutations in cancer development and progression.
Evaluation of p53-siRNA as a potential therapeutic agent for malignancies with TP53 abnormalities, such as bladder cancer, prostate cancer, and other solid tumors.
Studies on chemotherapy sensitization, as TP53 siRNA has shown synergistic effects with chemotherapeutic agents like cisplatin in inhibiting cancer cell viability.
Analysis of cell cycle regulation and apoptosis pathways mediated by p53, using gene silencing to elucidate downstream signaling cascades (e.g., PI3K/Akt pathway).
RNAi-based functional loss-of-phenotype studies to validate TP53 as a drug target for cancer treatment.

Customers interested in human conventional TP53 siRNA may also benefit from exploring other siRNA products targeting genes in the p53 signaling pathway or tumor suppressor network. These include siRNAs specific to PERP (a p53 apoptosis effector), RPRM (a TP53-dependent G2 arrest mediator), and other tumor-related genes such as those involved in cell cycle regulation and apoptosis. Additionally, species-specific TP53 siRNAs for mouse and rat models are available to support cross-species research comparisons. If you are interested in related products, you can contact us directly or request product customization services.